Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sells 10,000 Shares of Stock

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the transaction, the director now owns 228,816 shares in the company, valued at $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

TG Therapeutics Stock Down 1.1%

Shares of TGTX traded down $0.38 during midday trading on Monday, hitting $35.63. The company had a trading volume of 1,297,570 shares, compared to its average volume of 2,638,647. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a 1 year low of $16.21 and a 1 year high of $46.48. The firm has a market capitalization of $5.66 billion, a P/E ratio of -356.26 and a beta of 1.94. The company's 50-day simple moving average is $37.24 and its 200-day simple moving average is $34.80.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The firm had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm's revenue for the quarter was up 90.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.07) EPS. As a group, sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on TGTX. HC Wainwright reissued a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, TG Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $40.80.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TGTX. Empowered Funds LLC increased its holdings in TG Therapeutics by 6.1% during the 4th quarter. Empowered Funds LLC now owns 49,267 shares of the biopharmaceutical company's stock valued at $1,483,000 after acquiring an additional 2,836 shares in the last quarter. Van ECK Associates Corp purchased a new stake in TG Therapeutics in the fourth quarter valued at approximately $4,219,000. New York State Teachers Retirement System increased its holdings in shares of TG Therapeutics by 1.9% during the 4th quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock worth $1,317,000 after buying an additional 837 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares during the period. Finally, Valeo Financial Advisors LLC raised its holdings in TG Therapeutics by 32.4% in the fourth quarter. Valeo Financial Advisors LLC now owns 13,532 shares of the biopharmaceutical company's stock valued at $407,000 after buying an additional 3,309 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.